Subscribe to RSS
DOI: 10.1055/s-0042-1759566
Clinical Epidemiology of Pediatric Coronavirus Disease 2019 and its Postacute Sequelae
Funding This work was supported, in part, by grants from the National Institutes of Health (NIH; grant no.: K23AI159518; to C.R.O). Contents are solely the responsibility of the authors and do not necessarily reflect the views of the foundation or the NIH. No honorarium, grant, or other forms of payment was given to anyone to produce the manuscript.![](https://www.thieme-connect.de/media/srccm/202301/lookinside/thumbnails/10-1055-s-0042-1759566_230107-1.jpg)
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has affected individuals of all ages across. Although children generally experience a benign illness from COVID-19, the emergence of novel variants of the virus has resulted in significant changes in the morbidity and mortality rates for this age group. Currently, COVID-19 is the eighth leading cause of pediatric deaths in the United States. In addition to acute respiratory illness, some children can develop a severe postinfectious condition known as a multisystem inflammatory syndrome in children, which can progress to rapid-onset cardiogenic shock. Recovery from COVID-19 can also be slow for some children, resulting in persistent or reoccurring symptoms for months, commonly referred to as long COVID. These postinfectious sequelae are often distressing for children and their parents, can negatively impact the quality of life, and impose a considerable burden on the health care system. In this article, we review the clinical epidemiology of pediatric COVID-19 and outline the management considerations for its acute and postacute manifestations.
Publication History
Article published online:
16 January 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 WHO. COVID-19 Weekly Epidemiological Update. 2022 April 27, 2022 at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
- 2 Shi DS, Whitaker M, Marks KJ. et al; COVID-NET Surveillance Team. Hospitalizations of children aged 5-11 years with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep 2022; 71 (16) 574-581
- 3 Radhakrishnan L, Leeb RT, Bitsko RH. et al. Pediatric emergency department visits associated with mental health conditions before and during the COVID-19 pandemic—United States, January 2019-January 2022. MMWR Morb Mortal Wkly Rep 2022; 71 (08) 319-324
- 4 Flaxman S, Whittaker C, Semenova E. et al. Covid-19 is a leading cause of death in children and young people ages 0–19 years in the United States. medRxiv 2022; (e-pub ahead of print). DOI: 10.1101/2022.05.23.22275458.
- 5 Belhadjer Z, Méot M, Bajolle F. et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation 2020; 142 (05) 429-436
- 6 Buonsenso D, Munblit D, De Rose C. et al. Preliminary evidence on long COVID in children. Acta Paediatr 2021; 110 (07) 2208-2211
- 7 Zirinsky E, Paintsil E, Oliveira CR. The clinical epidemiology of coronavirus disease 2019 in children and adolescents mirrors the widening gap in healthcare disparities. Curr Opin Pediatr 2021; 33 (03) 281-285
- 8 Hillis SD, Blenkinsop A, Villaveces A. et al. COVID-19-associated orphanhood and caregiver death in the United States. Pediatrics 2021; (e-pub ahead of print) DOI: 10.1542/peds.2021-053760.
- 9 Fernandes DM, Oliveira CR, Guerguis S. et al. Severe Acute Respiratory Syndrome Coronavirus 2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth. J Pediatr 2021; 230: 23-31.e10
- 10 Pham S, Porta G, Biernesser C. et al. The burden of bereavement: early-onset depression and impairment in youths bereaved by sudden parental death in a 7-year prospective study. Am J Psychiatry 2018; 175 (09) 887-896
- 11 Feeding America. The impact of coronavirus on food insecurity. Accessed 9 May 2022 at: https://www.feedingamerica.org/research/coronavirus-hunger-research
- 12 Cooper DM, Afghani B, Byington CL. et al. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Pediatr Res 2021; 90 (05) 966-970
- 13 Loades ME, Chatburn E, Higson-Sweeney N. et al. Rapid systematic review: the impact of social isolation and loneliness on the mental health of children and adolescents in the context of COVID-19. J Am Acad Child Adolesc Psychiatry 2020; 59 (11) 1218-1239.e3
- 14 Dunton GF, Do B, Wang SD. Early effects of the COVID-19 pandemic on physical activity and sedentary behavior in children living in the U.S. BMC Public Health 2020; 20 (01) 1351
- 15 Meinck S, Julian F, Strietholt R. The Impact of the COVID-19 Pandemic on Education: International Evidence from the Responses to Educational Disruption Survey (REDS). Accessed 21 November 2022 at https://unesdoc.unesco.org/ark:/48223/pf0000380398.locale=en
- 16 American Academy of Pediatrics. Children and COVID-19: state-level data report. Summary of findings. Accessed June 26, 2022 at: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/
- 17 Centers for Disease Control and Prevention. COVID Data Tracker. Pediatric Data. US Department of Health and Human Services, CDC. Accessed June 26, 2022 at: https://covid.cdc.gov/covid-data-tracker/#pediatric-data
- 18 Dawood FS, Porucznik CA, Veguilla V. et al. Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in Utah and New York City, New York. JAMA Pediatr 2022; 176 (01) 59-67
- 19 Peaper DR, Murdzek C, Oliveira CR. et. al. Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Children in a Large Regional US Health System During the Coronavirus Disease 2019 Pandemic. Pediatr Infect Dis J 2021; 40 (03) 175-181
- 20 Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med 2021; 174 (01) 69-79
- 21 Madewell ZJ, Yang Y, Longini Jr IM, Halloran ME, Dean NE. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. JAMA Netw Open 2021; 4 (08) e2122240
- 22 Lopez AS, Hill M, Antezano J. et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities—Salt Lake City, Utah, April-July 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (37) 1319-1323
- 23 Huff HV, Singh A. Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies. Clin Infect Dis 2020; 71 (10) 2752-2756
- 24 Chu VT, Yousaf AR, Chang K. et al; Georgia Camp Investigation Team. Household transmission of SARS-CoV-2 from children and adolescents. N Engl J Med 2021; 385 (10) 954-956
- 25 Okarska-Napierała M, Mańdziuk J, Kuchar E. SARS-CoV-2 cluster in nursery, Poland. Emerg Infect Dis 2021;27(01):
- 26 Duval D, Palmer JC, Tudge I. et al. Long distance airborne transmission of SARS-CoV-2: rapid systematic review. BMJ 2022; 377: e068743
- 27 Liguoro I, Pilotto C, Bonanni M. et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr 2020; 179 (07) 1029-1046
- 28 Forrest CB, Burrows EK, Mejias A. et al. Severity of acute COVID-19 in children <18 years old March 2020 to December 2021. Pediatrics 2022; 149 (04) e2021055765
- 29 Delahoy MJ, Ujamaa D, Taylor CA. et al. Comparison of influenza and COVID-19-associated hospitalizations among children < 18 years old in the United States-FluSurv-NET (October-April 2017-2021) and COVID-NET (October 2020-September 2021). Clin Infect Dis 2022; ciac388
- 30 American Academy of Pediatrics. Children and COVID-19: State-Level Data Report Accessed 9 May 2022 at: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/
- 31 Tso WWY, Kwan MYW, Wang YL. et al. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. Emerg Microbes Infect 2022; 11 (01) 1742-1750
- 32 Hui KPY, Ho JCW, Cheung MC. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 2022; 603 (7902): 715-720
- 33 Tunç EM, Shin CKJ, Usoro E. et al. Croup during the coronavirus disease 2019 Omicron variant surge. J Pediatr 2022; 247: 147-149
- 34 Brewster RC, Parsons C, Laird-Gion J. et al. COVID-19-associated croup in children. Pediatrics 2022; 149 (06) e2022056492
- 35 Acker KP, Levine DA, Varghese M. et al. Indications for hospitalization in children with SARS-CoV-2 infection during the Omicron wave in New York city. Children (Basel) 2022; 9 (07) 1043
- 36 Harwood R, Yan H, Talawila Da Camara N. et al. Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: a systematic review and individual patient meta-analysis. EClinicalMedicine 2022; 44: 101287
- 37 Stokes EK, Zambrano LD, Anderson KN. et al. Coronavirus disease 2019 case surveillance—United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (24) 759-765
- 38 Mark EG, Golden WC, Gilmore MM. et al. Community-onset severe acute respiratory syndrome coronavirus 2 infection in young infants: a systematic review. J Pediatr 2021; 228: 94-100.e3
- 39 Fink EL, Robertson CL, Wainwright MS. et al; Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID) Investigators. Prevalence and risk factors of neurologic manifestations in hospitalized children diagnosed with acute SARS-CoV-2 or MIS-C. Pediatr Neurol 2022; 128: 33-44
- 40 Valderas C, Méndez G, Echeverría A, Suarez N, Julio K, Sandoval F. COVID-19 and neurologic manifestations: a synthesis from the child neurologist's corner. World J Pediatr 2022; 18 (06) 373-382
- 41 American Academy of Pediatrics. Critical Updates on COVID-19. Clinical Guidance. COVID-19 Testing Guidance. Accessed June 30, 2022 at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-testing-guidance/
- 42 Raissaki M, Shelmerdine SC, Damasio MB. et al. Management strategies for children with COVID-19: ESPR practical recommendations. Pediatr Radiol 2020; 50 (09) 1313-1323
- 43 Chiotos K, Hayes M, Kimberlin DW. et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc 2021; 10 (01) 34-48
- 44 Beigel JH, Tomashek KM, Dodd LE. et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19—final report. N Engl J Med 2020; 383 (19) 1813-1826
- 45 Goldman DL, Aldrich ML, Hagmann SHF. et al. Compassionate use of remdesivir in children with severe COVID-19. Pediatrics 2021; 147 (05) e2020047803
- 46 Gottlieb RL, Vaca CE, Paredes R. et al; GS-US-540-9012 (PINETREE) Investigators. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022; 386 (04) 305-315
- 47 FDA. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. July 25, 2022 at: https://www.fda.gov/media/155050/download
- 48 Boonyaratanakornkit J, Boeckh M, Waghmare A. Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections. Curr Opin Infect Dis 2022; 35 (04) 280-287
- 49 Gupta A, Gonzalez-Rojas Y, Juarez E. et al; COMET-ICE Investigators. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 2022; 327 (13) 1236-1246
- 50 Weinreich DM, Sivapalasingam S, Norton T. et al; Trial Investigators. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med 2021; 385 (23) e81
- 51 Sherman G, Lamb G, Sharma T. et. al. Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: a multicenter retrospective study. J Pediatric Infect Dis Soc 2022
- 52 Iketani S, Liu L, Guo Y. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 2022; 604 (7906): 553-556
- 53 Wolf J, Abzug MJ, Anosike BI. et al. Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents. J Pediatric Infect Dis Soc 2022; 11 (05) 177-185
- 54 Sterne JAC, Murthy S, Diaz JV. et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020; 324 (13) 1330-1341
- 55 Marrone A, Nevola R, Sellitto A. et al. Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study. Clin Infect Dis 2022; 75 (01) e403-e409
- 56 Henderson LA, Canna SW, Friedman KG. et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 2. Arthritis Rheumatol 2021; 73 (04) e13-e29
- 57 Venn AMR, Schmidt JM, Mullan PC. Pediatric croup with COVID-19. Am J Emerg Med 2021; 43: 287.e1-287.e3
- 58 Park S, You J, Lee J, Park E. Two case reports of life-threatening croup caused by the SARS-CoV-2 Omicron BA.2 variant in pediatric patients. J Korean Med Sci 2022; 37 (24) e192
- 59 Cherry JD. Clinical practice. Croup. N Engl J Med 2008; 358 (04) 384-391
- 60 Ledwith CA, Shea LM, Mauro RD. Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of croup. Ann Emerg Med 1995; 25 (03) 331-337
- 61 Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Accessed June 26, 2022 at: https://emergency.cdc.gov/han/2020/han00432.asp
- 62 Payne AB, Gilani Z, Godfred-Cato S. et al; MIS-C Incidence Authorship Group. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open 2021; 4 (06) e2116420
- 63 Feldstein LR, Tenforde MW, Friedman KG. et al; Overcoming COVID-19 Investigators. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 2021; 325 (11) 1074-1087
- 64 Zambrano LD, Newhams MM, Olson SM. et. al. BNT162b2 mRNA Vaccination Against COVID-19 is Associated with Decreased Likelihood of Multisystem Inflammatory Syndrome in U.S. Children Ages 5-18 Years. Clin Infect Dis 2022; Aug 4: ciac637
- 65 Oliveira CR, Niccolai LM, Sheikha H. et. al. Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents. JAMA Netw Open 2022; Mar 1; 5 (03) e220935
- 66 Ahmed M, Advani S, Moreira A. et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine 2020;26(100527)
- 67 Choi NH, Fremed M, Starc T. et al. MIS-C and cardiac conduction abnormalities. Pediatrics 2020; 146 (06) e2020009738
- 68 Sperotto F, Friedman KG, Son MBF, VanderPluym CJ, Newburger JW, Dionne A. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr 2021; 180 (02) 307-322
- 69 Godfred-Cato S, Abrams JY, Balachandran N. et al. Distinguishing multisystem inflammatory syndrome in children from COVID-19, Kawasaki disease and toxic shock syndrome. Pediatr Infect Dis J 2022; 41 (04) 315-323
- 70 COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed June 26, 2022 at: https://www.covid19treatmentguidelines.nih.gov/
- 71 Whitworth H, Sartain SE, Kumar R. et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood 2021; 138 (02) 190-198
- 72 Goldenberg NA, Sochet A, Albisetti M. et al; Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee of the ISTH SSC. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost 2020; 18 (11) 3099-3105
- 73 Molteni E, Sudre CH, Canas LS. et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health 2021; 5 (10) 708-718
- 74 US Centers for Disease Control and Prevention. Post-COVID conditions. Accessed July 1, 2022 at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/
- 75 Behnood SA, Shafran R, Bennett SD. et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis of controlled and uncontrolled studies. J Infect 2022; 84 (02) 158-170
- 76 Munblit D, Buonsenso D, Sigfrid L, Vijverberg SJH, Brackel CLH. Post-COVID-19 condition in children: a COS is urgently needed. Lancet Respir Med 2022; 10 (07) 628-629
- 77 Zimmermann P, Pittet LF, Curtis N. The challenge of studying long COVID: an updated review. Pediatr Infect Dis J 2022; 41 (05) 424-426
- 78 Drogalis-Kim D, Kramer C, Duran S. Ongoing dizziness following acute COVID-19 infection: a single center pediatric case series. Pediatrics 2022; 150 (02) e2022056860
- 79 Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc Health 2021; 5 (06) e22-e23
- 80 Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med 2022; 28 (05) 911-923
- 81 Oliveira CR, Shapiro ED. Update on persistent symptoms associated with Lyme disease. Curr Opin Pediatr 2015; 27 (01) 100-104
- 82 Barrett CE, Koyama AK, Alvarez P. et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years—United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep 2022; 71 (02) 59-65
- 83 El-Hor N, Adams M. Pediatric rheumatologic effects of COVID-19. Pediatr Clin North Am 2021; 68 (05) 1011-1027
- 84 Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children—a nationwide cohort study. Eur J Pediatr 2022; 181 (04) 1597-1607
- 85 Goel A, Ranjan P, Klanidhi KB. et al. Comprehensive treatment module for medically unexplained physical symptoms—a guide for general practitioners. Cureus 2021; 13 (07) e16263
- 86 Bonvanie IJ, Kallesøe KH, Janssens KAM, Schröder A, Rosmalen JGM, Rask CU. Psychological interventions for children with functional somatic symptoms: a systematic review and meta-analysis. J Pediatr 2017; 187: 272-281.e17